NCT04191421View on ClinicalTrials.gov

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
BIOLOGICAL

Siltuximab

Given IV

BIOLOGICAL

Spartalizumab

Given IV

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (2)

Novartis
EUSA Pharma, Inc.
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

EUSA Pharma, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER